---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-23-000083"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:46:38.792925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q3 revenue $191.9M, up 23% YoY; raises FY2023 guidance, introduces FY2024 guidance

## Summary
- Q3 revenue $191.9M (+23% YoY); GAAP EPS -$0.75, adjusted EPS -$0.03.
- Testing volume ex-SneakPeek +18% YoY; hereditary cancer +18%, prenatal +20%, GeneSight +19%.
- Raised FY2023 revenue guidance to $747-753M (prev $730-750M); introduced FY2024 guidance $815-835M.
- Settled Ravgen litigation for $12.75M plus contingent $21.25M; expanded credit facility to $115M.
- New UnitedHealthcare contract effective Jan 1, 2024 through 2027; appointed Sam Raha COO effective Dec 11.

## SEC filing metadata
- accession: 0000899923-23-000083
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/0000899923-23-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/mygn-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-23-000083
- JSON: https://secwatch.observer/filing/0000899923-23-000083.json
- Plain text: https://secwatch.observer/filing/0000899923-23-000083.txt

## Key facts
- Earnings Releases
  MYRIAD GENETICS INC reported three months ended September 30, 2023 results: revenue $191.9 million, EPS $(0.75). Guidance raised.
  - Period: three months ended September 30, 2023
  - Revenue: $191.9 million
  - EPS: $(0.75)
  - Guidance: raised
  - Result: reported results
  source text: respectively. ▪ Prenatal test volumes grew 20% and 14% year-over-year, respectively, excluding contributions from the SneakPeek Early Gender DNA Test. • Third quarter revenue of $191.9 million, grew 23% year-over-year, inclusive of a $7.1 million change of estimate 1 in the current quarter versus $(5.3) million change of estimate 1 in the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/899923/000089992323000083/0000899923-23-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.